Eli Lilly and Company (LLY)
Pretax margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) | US$ in thousands | 12,680,400 | 6,554,600 | 6,806,400 | 6,155,500 | 7,229,900 |
Revenue | US$ in thousands | 45,042,700 | 34,124,100 | 28,541,400 | 28,318,400 | 24,539,800 |
Pretax margin | 28.15% | 19.21% | 23.85% | 21.74% | 29.46% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $12,680,400K ÷ $45,042,700K
= 28.15%
The pretax margin of Eli Lilly and Company has shown some fluctuations over the years, with a noticeable decline from 29.46% in December 31, 2020 to 19.21% in December 31, 2023. However, there was a recovery to 28.15% by December 31, 2024. This indicates that the company's profitability before taxes experienced some challenges but managed to improve towards the end of the period. It would be advisable to further investigate the factors contributing to these fluctuations to understand the underlying dynamics impacting Eli Lilly's financial performance.
Peer comparison
Dec 31, 2024
Company name
Symbol
Pretax margin
Eli Lilly and Company
LLY
28.15%
Abbott Laboratories
ABT
16.90%
AbbVie Inc
ABBV
11.49%
Alkermes Plc
ALKS
28.18%
Amphastar P
AMPH
25.85%
ANI Pharmaceuticals Inc
ANIP
4.37%
Arcus Biosciences Inc
RCUS
-109.30%
Biomarin Pharmaceutical Inc
BMRN
19.04%
Bristol-Myers Squibb Company
BMY
-17.38%
Catalent Inc
CTLT
-23.44%
Catalyst Pharmaceuticals Inc
CPRX
23.73%